A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

This is a Phase I/II, Single arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With refractory Hypercalcemia of Malignancy.

Inclusion criteria

• Fully informed and signed informed consent.
• Male or female, Adults (>/=18 years).
• Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) > 12.5 mg/dL (3.1 mmol /L).
• Last IV bisphosphonate treatment must be >/= 7 days and </= 30 days before the screening corrected serum calcium; or Last hydration therapy must be >/= 24 hours before the screening corrected serum calcium（Incompatible bisphosphonate）.
• Adequate organ function.

Exclusion criteria

• Pregnancy.
• Hyperparathyroidism, or other granulomatous disease.
• Hepatitis b surface antigen positive.
• Hepatitis c antibody positive, or HIV antibody positive.
• Receiving dialysis for renal failure.
• Known sensitivity to JMT103 composition.
• Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of screening CSC.
• Treatment with cinacalcet within 4 weeks prior to the date of screening CSC.
• Currently participating another clinical study，or Four weeks or less since receiving an investigational product in another clinical study.
• In the opinion of the investigator , being unsuitable for inclusion in the study，or subjects withdraw informed consent.
• Treatment with monoclonal antibody to RANK ligand (RANKL) within 180 days prior to the date of the screening CSC.